MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Knight Therapeutics Company Profile (TSE:GUD)

Consensus Ratings for Knight Therapeutics (TSE:GUD) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: C$9.25

Analysts' Ratings History for Knight Therapeutics (TSE:GUD)
Show:
DateFirmActionRatingPrice TargetActions
6/7/2016TD SecuritiesLower Price TargetBuyC$10.00 -> C$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016CIBCReiterated RatingOutperformC$9.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016ScotiabankBoost Price TargetOutperformC$9.00 -> C$9.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2016Paradigm CapitalSet Price TargetBuyC$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016Dundee SecuritiesReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2015LaurentianLower Price TargetHoldC$9.50 -> C$8.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Knight Therapeutics (TSE:GUD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
8/15/2014($0.01)$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Knight Therapeutics (TSE:GUD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.06$0.06$0.06
Q2 20161$0.06$0.06$0.06
Q3 20161$0.04$0.04$0.04
Q4 20161$0.04$0.04$0.04
(Data provided by Zacks Investment Research)
Dividend History for Knight Therapeutics (TSE:GUD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Knight Therapeutics (TSE:GUD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/24/2015Robert Nathaniel LandeDirectorSell57,000C$8.85C$504,267.60Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Knight Therapeutics (TSE:GUD)
DateHeadline
06/20/16 07:43 AMKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : GUD-CA : June 20, 2016 -
06/16/16 05:00 PMKnight Therapeutics Inc. Announces Election of Directors -
06/03/16 04:38 PMThis company is cashed up for growth while limiting downside risk
06/02/16 04:34 PMKnight Therapeutics Completes Previously Announced Bought Deal of Common Shares, Including Exercise of Over-Allotment Option, for $230 million - ... NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Knight Therapeutics Inc. ("Knight") (TSX:GUD) today announced that it has completed its previously announced bought deal offering (the "Offering") for ...
05/31/16 07:00 AMKnight to Present at Both the National Bank Financial Quebec Conference in Montreal and the Jefferies Healthcare Conference in New York City -
05/26/16 01:14 PM3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and Receive Lead Order From and Enter Into ... - Marketwired (press release) - 3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and Receive Lead Order From and Enter Into ...Marketwired (press release)... to announce that they have increased their minimum financing from $3,000,000 to $5,000,000 (the "Financing") and entered into an advisory services agreement (the "Agreement") with Knight Therapeutics Inc. ("Knight") (TSX: GUD). Knight has committed ...and more »
02/26/16 01:20 PMKnight Therapeutics : Breaks Glass on Medimetriks Partnership - 01/25 KNIGHT THERAPEUTICS: INTEGA Skin Looks GUD to Knight 2015 KNIGHT THERAPEUTICS: Loan to Extenway Impaired 2015 KNIGHT THERAPEUTICS: Loan to Extenway Impaired 2015 KNIGHT THERAPEUTICS: Loan to Extenway Impaired
02/17/16 07:54 AMKnight Breaks Glass on Medimetriks Partnership -
02/01/16 07:00 AMBraeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense Agreement for PROBUPHINE® -
02/01/16 07:00 AMBraeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense Agreement for PROBUPHINE(R) -
01/25/16 10:00 AMINTEGA Skin Looks GUD to Knight -
About Knight Therapeutics

Knight Therapeutics logoKnight Therapeutics Inc. is a specialty pharmaceutical company. The Company's principal business activity is developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. The Company finances other life sciences companies in Canada and internationally with the goal of earning interest income and securing product distribution rights for Canada and select international markets. It invests in life sciences venture capital funds whereby the Company earns a return similar to any other limited partner in the fund and receives preferential access to healthcare products from around the world for Canada and select international markets. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO and VEWS Vascular Early Warning System.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: TSE
  • Symbol: GUD
  • CUSIP:
Key Metrics:
  • Previous Close: $8.30
  • 50 Day Moving Average: $8.28
  • 200 Day Moving Average: $7.68
  • P/E Ratio: 40.49
  • P/E Growth: -5736.00
  • Market Cap: $858.87M
  • Current Quarter EPS Consensus Estimate: $0.14 EPS
Additional Links:
Knight Therapeutics (TSE:GUD) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha